Insecticides (India)
- Market cap
- ₹ 1,510 Cr.
- P/E
- 12x
- P/B
- 1.28x
- 52-week range
- 507.05 – 775
- ROE
- 12%
- ROCE
- 16%
- Dividend yield
- 0.4%
- Debt / equity
- 0.13
- Sector
- Fertilizers & Agrochemicals
- Industry
- Pesticides & Agrochemicals
- Listed on
- NSE, BSE
About
Insecticides (India) Limited is an India-based company. The Company is engaged in the manufacturing activities of agricultural chemicals, pesticides and technical products for agricultural purposes. The Company caters to both domestic and international markets. The Company has a product range of approximately 100 products that include agricultural chemicals, household pesticides and biological products, which are being sold to the end consumer, which is farmers through channel partners. It also supplies products to international customers in approximately 30 countries with more than 100 customers through registrations. The Company’s product categories include insecticides, herbicides, fungicides, biologicals/plant growth regulators (PGR), Focus Maharatna and maharatna products. Its insecticide products include Mission SC, Bheema Plus, Milthion, Metacil, Turner, Supremo SP, Lethal Super 550, Dominant, Kunoichi, Hercules, Encounter, Bheema, Sargent SC, Super Star and others.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pesticides & Agrochemicals: 33 companies →Insecticides (India) against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)12 against a typical 23.6: cheaper than most peers (1st = cheapest).7th of 33
- Sales growth−11.4% against a typical −4.5% from a year earlier.23rd of 31
- Profit growth−24.1% against a typical +15.2% from a year earlier.19th of 25
- Share price, 3 months−18% against a typical −15.5%.20th of 32
- Size₹ 1,510.1 Cr. market value against a typical ₹ 883.3 Cr. (1st = largest).12th of 31
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Adequate safety
Rated A+ by CRISIL- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CRISIL | Crisil A+ | Stable | 25 Sep 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 25 Sep 2026 | Reaffirmed | Crisil A+ | — | CRISIL | ₹ 690 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 5 Nov 2026Upcoming | Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2026 and other business matters |
| 11 Aug 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2026 and other business matters |
| 28 May 2026 | Financial Results | To consider and approve the financial results for the quarter and financial year ended March 31, 2026 |
| 30 Jan 2026 | Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended December 31, 2025, dividend and other business matters |
| 12 Nov 2025 | Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2025 and other business matters |
| 13 Aug 2025 | Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2025 and other business matters |
| 28 May 2025 | Financial Results/Other business matters | To consider and approve the financial results for the period ended March 31, 2025 and other business matters |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 696 | 358 | 272 | 657 | 627 | 358 | 359 | 691 | 638 | 385 | 426 | 612 |
| Expenses | 614 | 332 | 264 | 585 | 538 | 327 | 330 | 607 | 548 | 358 | 401 | 544 |
| Operating Profit | 82 | 26 | 9 | 72 | 90 | 31 | 28 | 85 | 89 | 27 | 25 | 68 |
| OPM % | 12% | 7% | 3.3% | 11% | 14% | 9% | 8% | 12% | 14% | 7% | 6% | 11% |
| Other Income | 0 | 1 | 5 | 3 | 2 | 0 | 3 | 4 | 3 | 1 | 5 | 6 |
| Interest | 3 | 3 | 2 | 2 | 2 | 1 | 2 | 4 | 4 | 5 | 4 | 5 |
| Depreciation | 7 | 7 | 8 | 7 | 7 | 8 | 7 | 7 | 9 | 9 | 9 | 10 |
| Profit before tax | 72 | 17 | 4 | 66 | 82 | 22 | 22 | 77 | 79 | 14 | 16 | 59 |
| Tax % | 26% | 28% | −106% | 25% | 25% | 22% | 37% | 25% | 25% | 27% | 27% | 25% |
| Net Profit | 53 | 12 | 8 | 49 | 61 | 17 | 14 | 58 | 59 | 10 | 12 | 44 |
| EPS in Rs | 17.96 | 4.16 | 2.62 | 16.68 | 21.13 | 5.97 | 4.77 | 19.97 | 20.31 | 3.61 | 4.02 | 15.08 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 9%
- 5 Years
- 9%
- 3 Years
- 6%
- TTM
- 1%
- 10 Years
- 13%
- 5 Years
- 6%
- 3 Years
- 30%
- TTM
- −17%
- 10 Years
- 7%
- 5 Years
- 5%
- 3 Years
- 6%
- TTM
- —
- 10 Years
- 13%
- 5 Years
- 11%
- 3 Years
- 12%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Insecticides (India) | ₹ 515.70 | ₹ 1,510 Cr. | 12x | 1.3x | 12% | — |
| Asian Paints | ₹ 2,305.00 | ₹ 2,21,095 Cr. | 58.1x | 12.1x | 21.2% | 12.4% |
| Solar Industries India | ₹ 18,320.00 | ₹ 1,65,778 Cr. | 99.6x | 26.6x | 31.4% | 17.7% |
| Pidilite Industries | ₹ 1,514.00 | ₹ 1,54,107 Cr. | 64.8x | 14.7x | 23.8% | 16.9% |
| SRF | ₹ 2,309.00 | ₹ 68,444 Cr. | 44.6x | 6.1x | 13.8% | 11.6% |
| Linde India | ₹ 5,697.00 | ₹ 48,586 Cr. | 110.5x | 14.2x | 13.6% | 21.7% |
Management
- Hari Chand Aggarwal
- Chairman of the Board, Whole-time Director
- Sandeep Kumar Aggarwal
- Chief Financial Officer
- Devendra Kumar Ray
- Chief Operating Officer
- Dushyant Sood
- Chief Marketing Officer
- Sandeep Kumar
- Chief Compliance Officer, Company Secretary
- Rajesh Kumar Aggarwal
- Managing Director, Executive Director
- Sanskar Aggarwal
- Additional Whole Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.